Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Artiva Biotherapeutics, Inc.ARTV · Entity 5404 | President & Head of R&D | September 09, 2026 | September 11, 2026 |
| Contineum Therapeutics, Inc.CTNM · Entity 5311 | Director | June 26, 2026 | June 26, 2026 |
| NeuBase Therapeutics, Inc.NBSE · Entity 109568 | Director | September 09, 2020 | September 11, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Artiva Biotherapeutics, Inc.
Report date September 09, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 122,500 |
Reported balance
After 2026-09-09 transaction · row 1
1 source rowRow 1 · 2026-09-09 · Grant · Acquired 45,000 · Balance 122,500 F1: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.79 · Expires 2036-09-08 | Direct | 135,000 |
Reported balance
After 2026-09-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-09 · Grant · Acquired 135,000 · Balance 135,000 F2: Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
F2: Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period.
Contineum Therapeutics, Inc.
Report date June 26, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.19 · Expires 2036-06-25 | Direct | 19,000 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 19,000 · Balance 19,000 F1: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.
NeuBase Therapeutics, Inc.
Report date September 09, 2020 · Filed September 11, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.80 · Expires 2030-09-09 | Direct | 14,634 |
Reported balance
After 2020-09-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-09-09 · Grant · Acquired 14,634 · Balance 14,634 F1: 25% of the total shares shall vest on the first anniversary of September 9, 2020, and the remaining shares shall vest on an equal monthly basis over the following 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the total shares shall vest on the first anniversary of September 9, 2020, and the remaining shares shall vest on an equal monthly basis over the following 36 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2026 Filed Sep 11, 2026 22:37 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantEmployee Stock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $10.79 | $0.00 |
DisclosureSEC source: 0001193125-26-389514 · ownership.xml · derivative · entry 2 Miralles Gines Diego · CIK 0001773413 · President & Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2036-09-08 F2 · derivative.exercise_date: Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 22:37 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-389514 · ownership.xml · nonDerivative · entry 1 Miralles Gines Diego · CIK 0001773413 · President & Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,500 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 21:46 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $14.19 | $0.00 |
DisclosureSEC source: 0001628280-26-045845 · wk-form4_1782510384.xml · derivative · entry 1 Miralles Gines Diego · CIK 0001773413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Class A Common Stock · 19,000 shares Expires 2036-06-25 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| May 18, 2026 Filed May 19, 2026 12:11 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantEmployee Stock Option (Right to Buy) · Derivative | 232,500 | $0.00 Strike: $9.22 | $0.00 |
DisclosureSEC source: 0001193125-26-229727 · ownership.xml · derivative · entry 2 Miralles Gines Diego · CIK 0001773413 · President & Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,500 Underlying: Common Stock · 232,500 shares Expires 2036-05-17 F2 · shares: Represents stock option award granted under the Issuer's 2025 Inducement Plan. F3 · derivative.exercise_date: 25% of the shares initially subject to the option will vest and become exercisable on May 15, 2027, and the balance of the shares subject to the option shall vest and become exercisable at a rate of 1/36th per month over the following 36 months. Read SEC document |
| May 18, 2026 Filed May 19, 2026 12:11 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 77,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-229727 · ownership.xml · nonDerivative · entry 1 Miralles Gines Diego · CIK 0001773413 · President & Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,500 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Inducement Plan. Read SEC document |
| June 26, 2025 Filed Jun 26, 2025 21:39 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 14,750 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001437749-25-021365 · rdgdoc.xml · derivative · entry 1 Miralles Gines Diego · CIK 0001773413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,750 Underlying: Class A Common Stock · 14,750 shares Expires 2035-06-25 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 20:30 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantDirector Stock Option (Right to Buy) · Derivative | 13,750 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001415889-25-018276 · form4-06262025_040604.xml · derivative · entry 1 Miralles Gines Diego · CIK 0001773413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2035-06-23 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 20:12 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 29,500 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001437749-25-008003 · rdgdoc.xml · derivative · entry 1 Miralles Gines Diego · CIK 0001773413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,500 Underlying: Class A Common Stock · 29,500 shares Expires 2035-03-13 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan, pursuant to the Issuer's Non-Employee Director Compensation Program, as amended. One-third of the option shares vest on March 14, 2026, and the remainder vests in 24 equal monthly installments thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 17:20 UTC | NeuBase Therapeutics, Inc. NBSE · Entity 109568 | GrantStock option (right to buy) · Derivative | 14,634 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001104659-20-104491 · tm2030658d3_4.xml · derivative · entry 1 Miralles Gines Diego · CIK 0001773413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,634 Underlying: Common Stock · 14,634 shares Expires 2030-09-09 F1 · derivative.exercise_date: 25% of the total shares shall vest on the first anniversary of September 9, 2020, and the remaining shares shall vest on an equal monthly basis over the following 36 months. Read SEC document |
| July 12, 2019 Filed Jul 16, 2019 20:34 UTC | NeuBase Therapeutics, Inc. NBSE · Entity 109568 | GrantStock option (right to buy) · Derivative | 227,330 | $0.00 Strike: $5.39 | $0.00 |
DisclosureSEC source: 0001387131-19-005130 · ownership.xml · derivative · entry 1 Miralles Gines Diego · CIK 0001773413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,330 Underlying: Common stock · 227,330 shares Expires 2029-07-12 F1 · derivative.exercise_date: 1/36th of the total shares subject to the option shall vest monthly over three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.